Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, will give an investor briefing at the Alpha ex-100 Conference hosted by Morgan Stanley in Sydney today.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the formation of its Clinical Advisory Board for its world-first diagnostic blood test to identify esophageal cancer, specifically esophageal adenocarcinoma, PromarkerEso.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics has secured new intellectual property protection following the grant of a patent in Australia for the platform technology which precisely measures levels of oxidative stress.
Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce the successful unblinding and data analysis of its pivotal clinical trial for the Felix(TM) System, confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the WA Life Sciences Broker Meets Biotech event, Perth on 20th March 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the official launch of its first-in-class predictive test for diabetic kidney disease, Promarker(R)D, in Australia.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the publication of results of its landmark study demonstrating the PromarkerD test significantly outperforms the current standard of care tests in predicting future kidney function decline.
